[Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)]

Lorenzo Altomonte; Geltrude Mingrone; Giovanni Ghirlanda; Raffaele Manna; Antonio Giuseppe Rebuzzi; Ma Pala; Av Greco

[Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)]

Lorenzo Altomonte, Geltrude Mingrone, Giovanni Ghirlanda, Raffaele Manna, Antonio Giuseppe Rebuzzi, Ma Pala, Av Greco

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

The biliary lithogenous index before and after treatment with Etofibrate, a new hypolipaemizing substance, has been assessed in dyslipidaemic subjects (ypes II and IV). Etofibrate is the result of the association of a molecule of clofibrate and one of nicotinic acid. An analysis of relative molar concentrations of biliary lipides showed that subjects with type IV and IIb dyslipidaemia produced lithogenous bile in base condition, unlike subjects with type IIa dyslipidaemia. After 28 days of treatment with Etofibrate (900 mg/die) a clear-cut increase was observed in the biliary lithogenous index in all types of dyslipidaemia examined.

Titolo tradotto del contributo	[Autom. eng. transl.] Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)
Lingua originale	Italian
pagine (da-a)	273-278
Numero di pagine	6
Rivista	Minerva Medica
Volume	71
Stato di pubblicazione	Pubblicato - 1980

Keywords

Adult
Aged
Bile
Clofibrate
Clofibric Acid
Female
Humans
Hyperlipoproteinemia Type II
Hyperlipoproteinemia Type IV
Hypolipidemic Agents
Lipids
Male
Middle Aged

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{e930ee2add5841c6a7fc786b1fae289c,

title = "[Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)]",

abstract = "The biliary lithogenous index before and after treatment with Etofibrate, a new hypolipaemizing substance, has been assessed in dyslipidaemic subjects (ypes II and IV). Etofibrate is the result of the association of a molecule of clofibrate and one of nicotinic acid. An analysis of relative molar concentrations of biliary lipides showed that subjects with type IV and IIb dyslipidaemia produced lithogenous bile in base condition, unlike subjects with type IIa dyslipidaemia. After 28 days of treatment with Etofibrate (900 mg/die) a clear-cut increase was observed in the biliary lithogenous index in all types of dyslipidaemia examined.",

keywords = "Adult, Aged, Bile, Clofibrate, Clofibric Acid, Female, Humans, Hyperlipoproteinemia Type II, Hyperlipoproteinemia Type IV, Hypolipidemic Agents, Lipids, Male, Middle Aged, Adult, Aged, Bile, Clofibrate, Clofibric Acid, Female, Humans, Hyperlipoproteinemia Type II, Hyperlipoproteinemia Type IV, Hypolipidemic Agents, Lipids, Male, Middle Aged",

author = "Lorenzo Altomonte and Geltrude Mingrone and Giovanni Ghirlanda and Raffaele Manna and Rebuzzi, {Antonio Giuseppe} and Ma Pala and Av Greco",

year = "1980",

language = "Italian",

volume = "71",

pages = "273--278",

journal = "Minerva Medica",

issn = "0026-4806",

publisher = "Edizioni Minerva Medica",

}

TY - JOUR

T1 - [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)]

AU - Altomonte, Lorenzo

AU - Mingrone, Geltrude

AU - Ghirlanda, Giovanni

AU - Manna, Raffaele

AU - Rebuzzi, Antonio Giuseppe

AU - Pala, Ma

AU - Greco, Av

PY - 1980

Y1 - 1980

N2 - The biliary lithogenous index before and after treatment with Etofibrate, a new hypolipaemizing substance, has been assessed in dyslipidaemic subjects (ypes II and IV). Etofibrate is the result of the association of a molecule of clofibrate and one of nicotinic acid. An analysis of relative molar concentrations of biliary lipides showed that subjects with type IV and IIb dyslipidaemia produced lithogenous bile in base condition, unlike subjects with type IIa dyslipidaemia. After 28 days of treatment with Etofibrate (900 mg/die) a clear-cut increase was observed in the biliary lithogenous index in all types of dyslipidaemia examined.

AB - The biliary lithogenous index before and after treatment with Etofibrate, a new hypolipaemizing substance, has been assessed in dyslipidaemic subjects (ypes II and IV). Etofibrate is the result of the association of a molecule of clofibrate and one of nicotinic acid. An analysis of relative molar concentrations of biliary lipides showed that subjects with type IV and IIb dyslipidaemia produced lithogenous bile in base condition, unlike subjects with type IIa dyslipidaemia. After 28 days of treatment with Etofibrate (900 mg/die) a clear-cut increase was observed in the biliary lithogenous index in all types of dyslipidaemia examined.

KW - Adult

KW - Aged

KW - Bile

KW - Clofibrate

KW - Clofibric Acid

KW - Female

KW - Humans

KW - Hyperlipoproteinemia Type II

KW - Hyperlipoproteinemia Type IV

KW - Hypolipidemic Agents

KW - Lipids

KW - Male

KW - Middle Aged

KW - Adult

KW - Aged

KW - Bile

KW - Clofibrate

KW - Clofibric Acid

KW - Female

KW - Humans

KW - Hyperlipoproteinemia Type II

KW - Hyperlipoproteinemia Type IV

KW - Hypolipidemic Agents

KW - Lipids

KW - Male

KW - Middle Aged

UR - http://hdl.handle.net/10807/6297

M3 - Articolo in rivista

SN - 0026-4806

VL - 71

SP - 273

EP - 278

JO - Minerva Medica

JF - Minerva Medica

ER -

[Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)]

Abstract

Keywords

Altri file e collegamenti

Fingerprint

Cita questo